Biogen [BIIB] vs Eli Lilly and [LLY] Detailed Stock Comparison

Biogen

NASDAQ
Loading...

Eli Lilly and

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Biogen wins in 9 metrics, Eli Lilly and wins in 10 metrics, with 0 ties. Eli Lilly and appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricBiogenEli Lilly andBetter
P/E Ratio (TTM)15.3054.79Biogen
Price-to-Book Ratio1.3341.22Biogen
Debt-to-Equity Ratio37.40217.89Biogen
PEG Ratio1.920.60Eli Lilly and
EV/EBITDA8.4731.91Biogen
Profit Margin (TTM)15.31%25.91%Eli Lilly and
Operating Margin (TTM)34.61%45.81%Eli Lilly and
EBITDA Margin (TTM)34.61%45.81%Eli Lilly and
Return on Equity9.13%86.29%Eli Lilly and
Return on Assets (TTM)5.62%16.55%Eli Lilly and
Free Cash Flow (TTM)$2.52B$414.30MBiogen
Dividend YieldN/A0.52%N/A
1-Year Return-18.22%-9.34%Eli Lilly and
Price-to-Sales Ratio (TTM)2.3414.14Biogen
Enterprise Value$27.28B$790.49BEli Lilly and
EV/Revenue Ratio2.7314.84Biogen
Gross Profit Margin (TTM)77.13%84.27%Eli Lilly and
Revenue per Share (TTM)$68$59Biogen
Earnings per Share (Diluted)$10.45$15.33Eli Lilly and
Beta (Stock Volatility)0.130.46Biogen
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Biogen vs Eli Lilly and Stock Performance Analysis

Loading Price Chart...

Biogen
Eli Lilly and
Biogen Stock Overview | Eli Lilly and Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Biogen-3.65%11.21%8.98%18.38%29.25%2.70%
Eli Lilly and0.62%16.32%14.41%9.34%16.76%8.61%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Biogen-18.22%-41.79%-44.98%-43.44%167.17%305.18%
Eli Lilly and-9.34%155.00%478.33%936.74%2,137.95%1,505.95%

News Based Sentiment: Biogen vs Eli Lilly and

Biogen

News based Sentiment: POSITIVE

October proved to be a pivotal month for Biogen, driven by the promising Phase III results for Lecanemab, a potential blockbuster Alzheimer's drug. This, combined with strategic partnerships, regulatory approvals, and strong financial performance, significantly strengthens the company's long-term outlook and justifies a positive investment sentiment.

View Biogen News Sentiment Analysis

Eli Lilly and

News based Sentiment: POSITIVE

Eli Lilly delivered impressive Q2 earnings, secured major contracts, and made significant investments in manufacturing and international expansion. While a pipeline setback and insider selling introduce some caution, the overall narrative is strongly positive, driven by successful clinical trials and favorable analyst ratings.

View Eli Lilly and News Sentiment Analysis

Performance & Financial Health Analysis: Biogen vs Eli Lilly and

MetricBIIBLLY
Market Information
Market Cap i$23.44B$760.94B
Market Cap CategoryLarge capMega cap
10 Day Avg. Volume i1,927,0004,542,120
90 Day Avg. Volume i1,761,4533,880,340
Last Close$154.05$845.05
52 Week Range$110.04 - $194.13$623.78 - $937.00
% from 52W High-20.65%-9.81%
All-Time High$480.18 (Mar 16, 2015)$972.53 (Aug 19, 2024)
% from All-Time High-67.92%-13.11%
Growth Metrics
Quarterly Revenue Growth0.07%0.38%
Quarterly Earnings Growth0.09%0.91%
Financial Health
Profit Margin (TTM) i0.15%0.26%
Operating Margin (TTM) i0.35%0.46%
Return on Equity (TTM) i0.09%0.86%
Debt to Equity (MRQ) i37.40217.89
Cash & Liquidity
Book Value per Share (MRQ)$120.29$20.38
Cash per Share (MRQ)$18.82$3.95
Operating Cash Flow (TTM) i$2.12B$10.94B
Levered Free Cash Flow (TTM) i$2.27B$-2,265,437,440
Dividends
Last 12-Month Dividend Yield iN/A0.52%
Last 12-Month Dividend iN/A$4.10

Valuation & Enterprise Metrics Analysis: Biogen vs Eli Lilly and

MetricBIIBLLY
Price Ratios
P/E Ratio (TTM) i15.3054.79
Forward P/E i9.6037.06
PEG Ratio i1.920.60
Price to Sales (TTM) i2.3414.14
Price to Book (MRQ) i1.3341.22
Market Capitalization
Market Capitalization i$23.44B$760.94B
Enterprise Value i$27.28B$790.49B
Enterprise Value Metrics
Enterprise to Revenue i2.7314.84
Enterprise to EBITDA i8.4731.91
Risk & Other Metrics
Beta i0.130.46
Book Value per Share (MRQ) i$120.29$20.38

Financial Statements Comparison: Biogen vs Eli Lilly and

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)BIIBLLY
Revenue/Sales i$2.43B$15.56B
Cost of Goods Sold i$629.30M$2.45B
Gross Profit i$1.80B$13.11B
Research & Development i$434.10M$3.34B
Operating Income (EBIT) i$625.20M$7.13B
EBITDA i$831.80M$7.54B
Pre-Tax Income i$311.20M$6.78B
Income Tax i$70.70M$1.12B
Net Income (Profit) i$240.50M$5.66B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)BIIBLLY
Cash & Equivalents i$2.60B$3.09B
Total Current Assets i$7.63B$41.26B
Total Current Liabilities i$5.30B$30.07B
Long-Term Debt i$4.87B$34.50B
Total Shareholders Equity i$16.98B$15.85B
Retained Earnings i$19.50B$15.10B
Property, Plant & Equipment i$6.22BN/A

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)BIIBLLY
Operating Cash Flow i$518.90M$4.88B
Capital Expenditures i$-37.10M$-1.51B
Free Cash Flow i$212.20M$-1.60B
Debt Repayment i$0N/A
Common Stock Repurchase iN/A$-1.20B

Short Interest & Institutional Ownership Analysis

MetricBIIBLLY
Shares Short i5.13M7.32M
Short Ratio i3.351.93
Short % of Float i0.05%0.01%
Average Daily Volume (10 Day) i1,927,0004,542,120
Average Daily Volume (90 Day) i1,761,4533,880,340
Shares Outstanding i145.72M897.54M
Float Shares i146.23M895.44M
% Held by Insiders i0.00%0.00%
% Held by Institutions i0.93%0.84%

Dividend Analysis & Yield Comparison: Biogen vs Eli Lilly and

MetricBIIBLLY
Last 12-Month Dividend iN/A$4.10
Last 12-Month Dividend Yield iN/A0.52%
3-Year Avg Annual Dividend iN/A$4.02
3-Year Avg Dividend Yield iN/A0.22%
3-Year Total Dividends iN/A$12.05
Ex-Dividend DateN/AFeb 14, 2025